Articles tagged "Kidney transplantation"

2019 American Transplant Congress
Examination of a Novel Immunoregulatory Marker in Kidney and Lung Transplant Recipients
A. D. Desai¹, G. J. Kavalam², A. Chandraker², S. Tripathi²
¹1Harvard Summer Research Program for Kidney Medicine, Harvard Medical School,, Boston, MA, ²Schuster Family Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
*Purpose: The T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory receptor mainly expressed on T cells and NK cells. TIGIT has…
2019 American Transplant Congress
The Centennial Allograft? Observation Of Greater Than 100-year Allograft Survival Is More Common Among Liver Allograft Recipients Than Renal Allograft Recipients.
J. F. Renz, A. C. Gruessner, R. C. Misawa, A. Masi, R. W. Gruessner
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: We investigated the occurrence of deceased-donor liver (DDOLT), deceased-donor renal (DDRT), and living-donor renal allografts (LDRT) that have achieved 100 years or more of…
2019 American Transplant Congress
Long-Term Efficacy of Direct-Acting Antiviral Agents
J. Zhang, W. Sun, J. Lin, Y. Tian, L. Ma, L. Zhang, Y. Zhu
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: Long-term efficacy of direct-acting antiviral agents (DAAs) therapy in kidney transplant recipients was unknown. Thus, we aimed to evaluate it in a Chinese cohort…
2019 American Transplant Congress
Kidney Transplant Outcomes in Patients with ESRD Due to Myeloma
A. Riaz, A. Khalil, M. S. Yaqub, T. Taber, O. Adebiyi, A. Sharfuddin
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Recent literature has suggested that certain patients with multiple myeloma can successfully undergo renal transplantation after stem transplantation with consideration for maintenance therapy. Outcomes…
2019 American Transplant Congress
Novel Insights into Blocking the IL-6 / IL-6 Receptor Pathway after Pig Kidney Xenotransplantation in Baboons
H. Hara¹, G. Zhang¹, H. Iwase¹, T. Yamamoto¹, D. Ayares², D. E. Eckhoff¹, D. K. Cooper¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL, ²Revivicor Inc., Blacksburg, VA
*Purpose: IL-6 plays an important role in inflammation. The aims of the study were (i) to measure IL-6 in serum in baboons that received IL-6…
2019 American Transplant Congress
CMV Risk Status Remains a Relevant Risk Factor for Long-Term Outcomes
G. Karadkhele, W. Zhang, C. P. Larsen
Emory University, Atlanta, GA
*Purpose: Intensification of immunosuppression using T cell depleting induction has reduced rates of acute cellular rejection after kidney transplantation. Belatacept, a first in class T…
2019 American Transplant Congress
Bortezomib Based Induction Therapy Decreases Delayed Graft Function in High Risk Kidney Transplantation
K. Mahendran¹, N. Koizumi², J. K. Melancon¹
¹Transplant Institute, The George Washington University, Washington, DC, ²Schar School of Policy and Government, George Mason University, Arlington, VA
*Purpose: Over 100,000 candidates await a kidney transplant on the national United Network for Organ Sharing (UNOS) waitlist. Among these candidates, one-third have pre-formed antibodies…
2019 American Transplant Congress
Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study
H. Tedesco Silva¹, F. Citterio¹, M. Henry¹, T. R. Srinivas¹, Y. Watarai¹, S. Steinberg¹, N. Basic-Jukic¹, V. D. Garcia¹, E. Mor¹, V. R. Peddi¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², J. Pascual¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: To compare the antirejection efficacy outcomes of an everolimus+reduced-exposure CNI (EVR+rCNI) vs mycophenolic acid+standard-exposure CNI (MPA+sCNI) regimen in renal transplant recipients (RTxRs) from the…
2019 American Transplant Congress
Preemptive Kidney Transplantation: Is There a Role for ABO Incompatible Transplantation?
M. N. Mustian¹, B. A. Shelton¹, P. A. MacLennan¹, R. D. Reed¹, G. McGwin¹, B. J. Orandi¹, D. Sawinski², V. Kumar¹, J. E. Locke¹
¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA
*Purpose: Barriers to kidney transplantation (KT) exist, including ABO incompatibility (ABOi) between potential living kidney donors and transplant candidates. Incompatible pairs can undergo desensitization or…
2019 American Transplant Congress
A Single-Center Experience with a 6-Month Regimen of Pneumocystis jiroveci Pneumonia Prophylaxis in HIV-Positive Kidney Transplant Recipients
C. Mejia¹, G. Malat², D. H. Lee³, S. Epstein¹, M. Harhay³, L. Levin Mizrahi³, K. Ranganna³
¹Drexel University, Philadelphia, PA, ²Hahnemann University Hospital, Philadelphia, PA, ³Medicine, Drexel University, Philadelphia, PA
*Purpose: Pneumocystis jiroveci pneumonia (PJP) prophylaxis is recommended for all kidney transplant recipients (KTR) for after transplant. HIV-positive KTRs represent a unique subset, and there…